Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback